Genscript Biotech Corporation (G51) - Net Assets

Latest as of December 2025: €3.96 Billion EUR ≈ $4.64 Billion USD

Based on the latest financial reports, Genscript Biotech Corporation (G51) has net assets worth €3.96 Billion EUR (≈ $4.64 Billion USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€4.85 Billion ≈ $5.67 Billion USD) and total liabilities (€888.59 Million ≈ $1.04 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible equity quality of Genscript Biotech Corporation to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric	Value
Current Net Assets	€3.96 Billion
% of Total Assets	81.69%
Annual Growth Rate	40.66%
5-Year Change	262.75%
10-Year Change	N/A
Growth Volatility	51.03

Genscript Biotech Corporation - Net Assets Trend (2016–2025)

This chart illustrates how Genscript Biotech Corporation's net assets have evolved over time, based on quarterly financial data. See defensive interval ratio of Genscript Biotech Corporation to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Genscript Biotech Corporation (2016–2025)

The table below shows the annual net assets of Genscript Biotech Corporation from 2016 to 2025. For live valuation and market cap data, see G51 stock market capitalisation.

Year	Net Assets	Change
2025-12-31	€3.96 Billion ≈ $4.64 Billion	-8.30%
2024-12-31	€4.32 Billion ≈ $5.05 Billion	+111.48%
2023-12-31	€2.04 Billion ≈ $2.39 Billion	+50.03%
2022-12-31	€1.36 Billion ≈ $1.59 Billion	+24.68%
2021-12-31	€1.09 Billion ≈ $1.28 Billion	+34.01%
2020-12-31	€815.59 Million ≈ $953.51 Million	+119.07%
2019-12-31	€372.30 Million ≈ $435.26 Million	-24.53%
2018-12-31	€493.30 Million ≈ $576.72 Million	+116.06%
2017-12-31	€228.32 Million ≈ $266.93 Million	+24.07%
2016-12-31	€184.02 Million ≈ $215.14 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Genscript Biotech Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 2136.2% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Retained Earnings	€1.82 Billion	45.91%
Other Components	€2.14 Billion	54.09%
Total Equity	€3.96 Billion	100.00%

Genscript Biotech Corporation Competitors by Market Cap

The table below lists competitors of Genscript Biotech Corporation ranked by their market capitalization.

Company	Market Cap
Zhejiang XinAn Chemical Industrial Group Co Ltd SHG:600596	$3.14 Billion
Asker Healthcare ST:ASKER	$3.14 Billion
Cal-Comp Electronics (Thailand) Public Company Limited TW:9105	$3.14 Billion
Graphic Packaging Holding Company NYSE:GPK	$3.15 Billion
Zealand Pharma A/S CO:ZEAL	$3.14 Billion
Société Anonyme des Bains de Mer et du Cercle des Étrangers à Monaco F:RJ8	$3.14 Billion
SF Diamond SHE:300179	$3.14 Billion
Mangalore Refinery and Petrochemicals Limited NSE:MRPL	$3.14 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Genscript Biotech Corporation's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 4,321,172,000 to 3,959,331,000, a change of -361,841,000 (-8.4%).
Net loss of 532,830,000 reduced equity.
Share repurchases of 225,142,000 reduced equity.
New share issuances of 6,019,000 increased equity.
Other factors increased equity by 390,112,000.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	€-532.83 Million	-13.46%
Share Repurchases	€225.14 Million	-5.69%
Share Issuances	€6.02 Million	+0.15%
Other Changes	€390.11 Million	+9.85%
Total Change	€-	-8.37%

Book Value vs Market Value Analysis

This analysis compares Genscript Biotech Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 0.68x
The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
The price-to-book ratio has decreased from 9.79x to 0.68x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2017-12-31	€0.13	€1.23	x
2018-12-31	€0.26	€1.23	x
2019-12-31	€0.20	€1.23	x
2020-12-31	€0.46	€1.23	x
2021-12-31	€0.42	€1.23	x
2022-12-31	€0.48	€1.23	x
2023-12-31	€0.66	€1.23	x
2024-12-31	€2.02	€1.23	x
2025-12-31	€1.81	€1.23	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Genscript Biotech Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -13.46%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -55.53%
• Asset Turnover: 0.20x
• Equity Multiplier: 1.23x
Recent ROE (-13.46%) is below the historical average (-3.07%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2016	14.73%	22.81%	0.51x	1.27x	€8.41 Million
2017	11.99%	17.11%	0.30x	2.32x	€4.34 Million
2018	4.43%	9.18%	0.25x	1.92x	€-26.65 Million
2019	-25.32%	-35.45%	0.31x	2.32x	€-135.19 Million
2020	-22.73%	-52.51%	0.27x	1.61x	€-295.12 Million
2021	-39.54%	-68.13%	0.23x	2.54x	€-435.84 Million
2022	-22.45%	-36.26%	0.25x	2.52x	€-327.91 Million
2023	-6.86%	-17.03%	0.17x	2.44x	€-234.58 Million
2024	68.54%	498.22%	0.11x	1.22x	€2.53 Billion
2025	-13.46%	-55.53%	0.20x	1.23x	€-928.76 Million

Industry Comparison

This section compares Genscript Biotech Corporation's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $2,614,309,982
Average return on equity (ROE) among peers: -42.65%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Genscript Biotech Corporation (G51)	€3.96 Billion	14.73%	0.22x	$3.14 Billion
PROQR THERAPEUTICS EO-04 (0PQ)	$66.68 Million	-96.62%	1.57x	$142.34 Million
TIZIANA LIFE SCIENCES LTD (0RP)	$5.54 Million	-319.56%	1.20x	$141.34 Million
Theravance Biopharma Inc (0TB)	$441.80 Million	197.40%	0.37x	$828.57 Million
I-MAB SPONS.ADS/1 -0001 (0VY)	$201.16 Million	-11.05%	0.06x	$171.71 Million
PreveCeutical Medical Inc (18H)	$-2.29 Million	0.00%	0.00x	$3.34 Million
Argen-X (1AE)	$4.10 Billion	-7.20%	0.11x	$41.67 Billion
WAVE LIFE SCIENCES LTD. (1U5)	$39.63 Million	-145.12%	5.94x	$1.10 Billion
BIOCURE TECHNOLOGY INC. (1WH)	$1.58 Million	-6.53%	0.28x	$960.84K
ZAI LAB LTD0000006 (1ZLB)	$1.05 Billion	-42.40%	0.17x	$1.82 Billion
BioNTech SE (22UA)	$20.25 Billion	4.60%	0.14x	$20.05 Billion

About Genscript Biotech Corporation

F:G51 Germany Biotechnology

Market Cap

$3.14 Billion

€2.69 Billion EUR

Market Cap Rank

#4879 Global

#807 in Germany

Share Price

€1.23

Change (1 day)

-3.91%

52-Week Range

€1.14 - €2.04

All Time High

€4.62